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There is growing evidence to suggest that bone marrow-derived mesenchy-
mal stem cells (BM-MSCs) are key players in tumour stroma. Here, we
investigated the cross-talk between BM-MSCs and osteosarcoma (OS) cells.
We revealed a strong tropism of BM-MSCs towards these tumour cells
and identified monocyte chemoattractant protein (MCP)-1, growth-regu-
lated oncogene (GRO)-a and transforming growth factor (TGF)-b1 as piv-
otal factors for BM-MSC chemotaxis. Once in contact with OS cells, BM-
MSCs trans-differentiate into cancer-associated fibroblasts, further increas-
ing MCP-1, GRO-a, interleukin (IL)-6 and IL-8 levels in the tumour
microenvironment. These cytokines promote mesenchymal to amoeboid
transition (MAT), driven by activation of the small GTPase RhoA, in OS
cells, as illustrated by the in vitro assay and live imaging. The outcome is a
significant increase of aggressiveness in OS cells in terms of motility, inva-
siveness and transendothelial migration. In keeping with their enhanced
transendothelial migration abilities, OS cells stimulated by BM-MSCs also
sustain migration, invasion and formation of the in vitro capillary network
of endothelial cells. Thus, BM-MSC recruitment to the OS site and the
consequent cytokine-induced MAT are crucial events in OS malignancy.
1. Introduction
Osteosarcoma (OS) is an aggressive primary malignant
bone tumour accounting for ~ 60% of all bone
sarcomas, affecting mainly paediatric patients. It is
characterized by early metastasis, primarily to the
lung, and tumour relapse (Gibbs et al., 2005; Meyers
et al., 2011). The clinical outcome for OS patients with
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metastatic or relapsed OS has remained unchanged
over the past 30 years, underlining the need for new
therapeutic strategies (Kansara et al., 2014).
Cancer cell plasticity is a key prerequisite for ensuring
metastatic dissemination of the tumour, and describes
the ability of cancer cells to change their migration style
in response to environmental conditions (Odenthal
et al., 2016). Tumour cells can move as individual cells
or collective groups. Additionally, invasive single cell
migration can be divided into mesenchymal style, char-
acterized by elongated cell morphology and strongly
dependent on extracellular matrix (ECM) proteolysis,
and amoeboid migration, showing a rounded cell mor-
phology and independence from ECM degradation and
adhesion (Friedl and Alexander, 2011; Sanz-Moreno
et al., 2008). During tumour progression, cancer cells
can switch between different motility styles to allow the
escape of tumour cells from the primary site and subse-
quent dissemination to distant organs (Friedl and Wolf,
2003). The epithelial-to-mesenchymal transition (EMT)
allows the trans-differentiation of a cell with epithelial
features into a motile mesenchymal cell. This is a com-
plex transcriptional programme that involves loss of
cell–cell junctions, adhesions to ECM and cell polarity.
These events are associated with achievement of migra-
tory and invasive abilities. In addition, a cell moving
with a mesenchymal style can undergo a transition into
amoeboid style motility, a process known as mesenchy-
mal-to-amoeboid transition (MAT; Friedl and Wolf,
2003). MAT is characterized by extensive changes in cell
morphology and cytoskeleton organization. Due to low
reliance on cell adhesion and ECM proteolysis, amoe-
boid motility is significantly faster and less energy-con-
suming compared with the mesenchymal mode.
Moreover, high cytoskeleton contractility may confer
the advantages of promoting intravasation and meta-
static dissemination of tumour cells (Friedl and Wolf,
2010; Sanz-Moreno et al., 2008).
Growing evidence indicates that bone marrow-
derived mesenchymal stem cells (BM-MSCs) represent
critical actors in the tumour microenvironment (Bar-
cellos-de-Souza et al., 2013; Cuiffo and Karnoub,
2012; Gwendal and Paula, 2016). Several studies have
demonstrated that inflammatory cytokines and growth
factors produced by different primary epithelial can-
cers can recruit BM-MSCs (Barcellos-de-Souza et al.,
2016; Cuiffo and Karnoub, 2012; Spaeth et al., 2008;
Tsukamoto et al., 2012; Xu et al., 2009). Once
recruited into the tumour stroma, BM-MSCs may sus-
tain tumour growth and progression in multiple ways.
Indeed, BM-MSCs may directly affect the malignancy
cancer cells (Karnoub et al., 2007; Xu et al., 2009),
support tumour angiogenesis (Au et al., 2008; Suzuki
et al., 2011), differentiate into other pro-tumourigenic
stromal cells, such as cancer-associated fibroblasts
(CAFs) and cancer-associated macrophages (CAMs)
(Barcellos-de-Souza et al., 2016; Mishra et al., 2008),
and act as immune-modulators to suppress both innate
and adaptive immune responses against cancer (Nauta
and Fibbe, 2007; Sotiropoulou and Papamichail,
2007). However, there is also evidence indicating an
anti-tumoural activity of BM-MSCs (Attar-Schneider
et al., 2016; Lee et al., 2013; Qiao et al., 2008). Indeed,
the role of BM-MSCs in promoting tumourigenesis is
still controversial and warrants further studies.
Here, we evaluated the in vitro effects of the cross-
talk between BM-MSCs and OS cells on tumour
malignancy. We have used the conditioned medium
(CM) derived from either BM-MSCs or three different
OS cell lines: SaOS-2, MG-63 and HOS. These cells
differ in chromosomal alterations, proliferation rate,
invasion behaviour and expression profiles of cytoki-
nes, growth factors and matrix proteins (Lauvrak
et al., 2013; Mohseny et al., 2011). We proved that
BM-MSCs are efficiently recruited by monocyte
chemoattractant protein (MCP)-1, growth-regulated
oncogene (GRO)-a and transforming growth factor
(TGF)-b1 produced by OS cells. Once in contact with
tumour cells, BM-MSCs enhance the levels of GRO-a,
MCP-1, interleukin (IL)-6 and IL-8 in the tumour
microenvironment. This pattern of cytokines is crucial
to promote a MAT in OS cells, with a consequent
increase in their motility, invasiveness and
transendothelial migration. Moreover, the cross-talk
between BM-MSCs and OS cells is crucial to promote
a strong activation of endothelial cells. Accordingly,
understanding whether this interplay is critical for
in vivo tumour progression could offer an array of
alternative targets to test in preclinical models for the
impairment of OS metastatic dissemination.
2. Materials and methods
2.1. Antibodies and reagents
The following antibodies were used for western blot
analysis: CollagenI-a1 (NB600-408, rabbit; Novus Bio-
logicals, Littleton, CO, USA), a-SMA (A2547, mouse),
Rac1 (07-1464, rabbit) and tubulin (T5168, mouse)
from Sigma-Aldrich (St. Louis, MO, USA) and RhoA
(sc-418, mouse, Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Secondary antibodies to the appro-
priate species were from Santa Cruz Biotechnology.
For the immunofluorescence experiments, FITC-
phalloidin (F432, Molecular Probes, Eugene, OR,
USA), anti-P-MLC (Ser 19) antibodies (3671, rabbit,
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Cell Signaling, Danvers, MA, USA) and secondary
antibodies conjugated with AlexaFluor 488 (A-11034,
Life Technologies Invitrogen, Carlsbad, CA, USA)
were used.
For the migration experiments, blocking antibodies
were used against: CXCR4 (555971, BD Bioscience,
Franklin Lakes, NJ, USA), MCP-1 (555055, BD Bio-
sciences), IL-6 (mabg-hil6-3, InvivoGen, San Diego,
CA, USA) and IL-8 (MAB208-100, R&D System,
Minneapolis, MN, USA). As control antibody, we
used normal mouse IgG control (sc-2025, Santa Cruz
Biotechnology). SB225002 [(N-(2-hydroxy-4-nitrophe-
nyl)-N0-(2-bromophenyl)urea, 559405] and Ilomastat
(GM 6001, 364205) were from Merck Millipore (Biller-
ica, MS, USA). TGF-b1R blocker (TbR blk, p17) was
developed by Digna Biotech (Pamplona, Spain) as pre-
viously described (Barcellos-de-Souza et al., 2016).
MatrigelTM Basement Membrane Matrix (356234)
was from BD Biosciences. Rho Activator (calpeptin,
CN01) was from Cytoskeleton, Inc. (Denver, CO,
USA); GST-Rhotekin (14-662) and recombinant
human TNF-a (300-01A) were from Peprotech (Pepro-
tech Inc, Rocky Hill, NJ, USA) and CellTraceTM car-
boxyfluorescein succinimidyl ester (CFSE, C34554)
was from Life Technologies.
2.2. Isolation and culture cells
Human OS cell lines (SaOS-2, MG-63 and HOS) and
human umbilical vein endothelial cells (HUVECs) were
purchased from Sigma Aldrich (ECACC). Tumour
cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) high glucose with 2 mM L-glutamine
(Euroclone, Milan, Italy) supplemented with fetal
bovine serum (FBS; 10% v/v, Euroclone) and peni-
cillin/streptomicin (P/S, 1% v/v, Euroclone), in cell
culture flasks until 70–80% cell confluence. HUVECs
were cultured in complete endothelial cell growth med-
ium (EBM-2 Basal Medium, Lonza, Basel, Switzer-
land) plus the SingleQuots Kit, supplemented with
2 mM L-glutamine, P/S (1% v/v) and FBS (10% v/v).
Human BM-MSCs used in this study were isolated
from healthy donors and characterized by Dr Bambi’s
Unit (AOU Meyer Hospital, Florence, Italy) as previ-
ously reported (Barcellos-de-Souza et al., 2016). BM-
MSCs were cultured in DMEM low glucose (Euro-
clone) containing FBS (10% v/v), 2 mM L-glutamine
and P/S (1% v/v) and used between passages 2 and 7.
2.3. Preparation of conditioned media (CM)
OS CM were obtained from 1 9 106 tumour cells
maintained in low glucose media deprived of serum (St
Med) for 48 h at 37 °C in 5% CO2 humidified atmo-
sphere. CM derived from untreated (BM-MSCs St)
and conditioned MSCs (BM-MSCs OS) were obtained
from BM-MSCs grown to sub-confluence and serum-
starved in low glucose media or stimulated with CM
from OS cells for 48 h. Media were then removed and
replaced with St Med (low glucose) for an additional
24 h. CM derived from the different experimental con-
ditions were harvested, clarified by centrifugation and
frozen at 80 °C until use.
2.4. In vitro migration assays
Migration assays were performed in Boyden Chamber
with 8-lm pore size filters (CC3422, CostarTM, Corn-
ing, NY, USA). In BM-MSC chemotaxis assays,
2.5 9 104 cells were serum-starved for 24 h and
allowed to migrate overnight toward CM from SaOS-
2, MG-63 and HOS cells. Untreated cells (St Med)
were used as control. Migrating cells were fixed,
stained and counted in four randomly chosen fields
(109) in bright field. In chemotaxis experiments with
inhibitors, BM-MSCs were starved overnight in the
presence or absence of 20 lgmL1 anti- CXCR4
blocking antibodies, 200 nM SB225002 and
100 lgmL1 TbR blk. Anti-MCP-1 neutralizing anti-
bodies 5 lgmL1 were added to CM 1 h before per-
forming the assays. Migration assays of HOS cells
were performed by treating 3.5 9 105 tumour cells
with CM BM-MSCs St or CM BM-MSCs OS for 24 h.
St Med was used as control. Then, 5 9 104 HOS cells
were allowed to migrate for 6 h toward complete med-
ium (FBS 10%). Invasion assays were achieved by
covering the upper compartment of the Boyden cham-
ber with 50 lgcm2 of reconstituted Matrigel. OS
cells were treated with CM from starved or tumour-
activated BM-MSCs for 36 h. Then 5 9 104 HOS and
1 9 105 SaOS-2 or MG-63 were allowed to migrate
toward complete medium (10% FBS) for 5 h, over-
night or 24 h, respectively. Transendothelial migration
was performed with OS cells treated as above and
stained with CFSE. Tumour cells (3 9 104 HOS and
8 9 104 MG-63 and SaOS-2) were seeded onto
5 9 104 HUVECs activated with 10 ngmL1 TNF-a
and allowed to migrate toward 500 lL of complete
medium (HOS for 5 h, MG-63 and SaOS-2 for 16 h).
In invasion and transendothelial migration assays with
inhibitors, conditioned HOS cells were treated or not
treated with neutralizing antibodies against IL-6
(5 lgmL1), IL-8 (10 lgmL1), MCP-1 (10 lgmL1)
and SB225002 (200 nM). To evaluate MMP depen-
dence, OS cells treated or not treated with BM-MSCs
CM were incubated overnight with 50 lM Ilomastat.
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The number of migrating cells was determined by
counting in four randomly chosen fields in an inverted
optical or fluorescent microscope for invasion and
transendothelial migration, respectively. Recruitment
assays of HUVECs were performed allowing migration
or invasion of 5 9 104 cells for 6 h toward CM
HOS St and CM HOS BM-MSCs. St Med was used as
negative control. Representative images of migration
assays are reported in Supporting Information.
2.5. Western blotting
Cells were lysated in RIPA buffer and 5–20 lg of total
proteins were loaded on precast SDS/PAGE gels (Bio-
Rad) as previously described (Taddei et al., 2014).
2.6. Collagen contraction assay
BM-MSCs 1.5 9 105 maintained for 24 h in St Med
or HOS CM were harvested and resuspended in a
DMEM solution containing 1 mgmL1 Collagen A
(L7220, Merck Millipore) as previously reported (Bar-
cellos-de-Souza et al., 2016). The area of each gel
(number of pixels) was determined using IMAGEJ.
2.7. Gelatin zymography
CM derived from untreated or conditioned MSCs was
collected, centrifuged and concentrated 10-fold with
Amicon Ultra 4 mL centrifugal filter (UFC800324,
Merck Millipore). Gelatin zymography was performed
as previously described (Taddei et al., 2014).
2.8. Pull-down assay
RhoA and Rac1 activity were determined as previously
reported (Taddei et al., 2014).
2.9. Confocal analysis
MG-63 treated with CM from tumour-activated BM-
MSCs CM was fixed in p-formaldehyde (4% v/v in
PBS) for 20 min, permeabilized in Triton X-100 (0.5 v/v
in PBS) for 5 min, then washed twice with bovine serum
albumin (BSA; 1% v/v) and FBS (5% v/v in PBS) solu-
tion and incubated overnight at 4 °C with primary anti-
bodies against P-MLC (1 : 100). After two washes with
PBS, cells were incubated with anti-rabbit AlexaFluor
488 antibodies (1 : 1000) and FITC-phalloidin for 1 h
at room temperature in the dark. As positive control,
we used 1 UmL1 Calpeptin, a RhoA activator. The
coverslips were mounted in Gel MountTM Aqueous
Mounting Medium (Sigma-Aldrich). A Nikon Eclipse
TE2000-U (Nikon, Tokyo, Japan) confocal microscope
was used for data acquisition.
2.10. Flow cytometry
Staining of BM-MSCs cultivated in St Med or treated
with CM from OS cells for 48 h was performed as pre-
viously described (Barcellos-de-Souza et al., 2016).
2.11. ELISA and cytokine antibody array
Cytokine concentration in CM from MG-63 cells and
from BM-MSCs was determined by ELISA single kits
for IL-1 alpha (EH2IL1A), IL-6 (EH2IL6), IL-8
(EH2IL8), IL-17 (EH2IL17), GRO-a (EHCXCL1),
MCP-1 (KHC1011), PDGF-BB (EHCSRP2), TGF-b1
(EHTGFBI) and TNF-a (EH3TNFA), according to
the manufacturer’s instructions (Invitrogen). The quali-
tative analysis of cytokines and growth factors pro-
duced by BM-MSCs was performed in CM obtained
from 7.5 9 105 cells grown in St Med or stimulated
with CM from HOS cells for 48 h. Cells were then
starved for a further 24 h and CM was collected, clari-
fied by centrifugation and analysed with Human Cyto-
kine Antibody Array C5 (AAH-CYT-5, RayBiotech,
Aachen, Germany) according to the manufacturer’s
protocol. Membranes were developed with strepta-
vidin-HRP chemiluminescence reaction and then
exposed to X-ray film. Pixel densities of detectable
spots were calculated using IMAGEJ software. The inten-
sity of each spot was normalized to the intensities
obtained using positive antibody array controls and
subtracted from the related background. Expression
values higher than 10 000 arbitrary units were set to
identify a cut-off for cytokines to be considered. The
same type of analysis was performed in CM obtained
from HOS cells stimulated or not stimulated with CM
from tumour-activated BM-MSCs to determine the rel-
ative amounts of pro-angiogenic factors.
2.12. RT-qPCR
Extraction and retrotranscription of total RNA were





were normalized to those obtained with b-2 microglob-
ulin: 50-AGTATGCCTGCCGTGTGAAC-30 (forward),
50-GCGGCATCTTCACAAACCTCCA-30 (reverse).
Results are the mean  SD of three different experi-
ments.
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2.13. Capillary morphogenesis assay
HUVECs 2 9 104 were starved overnight and added
to the Matrigel-coated well of a 96-well plate in
200 lL of CM from HOS St or HOS BM-MSCs. The
wells were photographed in three randomly chosen
fields after 6 h, with an inverted microscope (Leitz
DM IRB) equipped with CCD optics and a digital
analysis system. Results were quantified by counting
number of junctions for each field (109).
2.14. Cell migration in three-dimensional collagen
matrices
Reconstruction by time-lapse video microscopy and
confocal microscopy was performed on MG-63 cells.
Subconfluent MG-63 cells treated or not treated with
CM from tumour-activated BM-MSCs were detached
by EDTA (2 mM), washed, incorporated into three-
dimensional collagen lattice (1.67 mgmL1; native der-
mal bovine type I collagen; RD Systems) and monitored
Fig. 1. BM-MSCs migrate toward CM from OS cells and affect the invasive behaviour of tumour cells. (A) BM-MSCs were allowed to
migrate overnight toward CM from OS cells (SaOS-2, MG-63 and HOS). Starvation medium (St Med) was used control. Results are
expressed as mean  SEM of five biological replicates; *** P < 0.001 vs. St Med. (B) BM-MSCs starved for 24 h in the presence or
absence of neutralizing antibodies against CXCR4 (20 lgmL1) were allowed to migrate toward CM from OS cells. Results are expressed
as mean  SEM of three biological replicates. (C) ELISA of cytokines and growth factors in CM derived from MG-63 starved for 48 h
(mean  SD, n = 3 technical replicates). (D) BM-MSC migration toward CM from MG-63 with neutralizing antibodies against MCP-1
(5 lgmL1, a-MCP-1), blocking of GRO-a receptor (200 nM, SB 225002) and TGF-b1 receptor (100 lgmL1, TbR blk). Results are presented
as mean  SEM of three biological replicates; *** P < 0.001 vs. CM MG-63. (E) OS cells were mantained for 48 h in St Med or CM
obtained from BM-MSCs starved for 48 h. Cells were then allowed to invade or (F) transmigrate toward complete medium (FBS 10%).
Results are presented as mean  SEM of three biological replicates; * P < 0.05; ** P < 0.01; *** P < 0.005 vs. St Med.
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by time-lapse video microscopy (Br€ocker, 2004; Friedl,
2004). For three-dimensional time-lapse confocal micro-
scopy (Leica-SP5 system), cells within the lattice were
labelled by CFSE (360 ngmL1), scanned for 12 h at 3-
min time intervals for simultaneous fluorescence and
back scatter signal (reflection), and reconstructed.
Three-dimensional motility of cells is shown by time
lapse of xyzt analysis (three-dimensional analysis over
time).
2.15. Statistical analysis
One-way ANOVA followed by a Bonferroni comparison
test and Student’s t-test (two-tailed) were used to
determine statistical significance with a P-value thresh-
old set at < 0.05.
3. Results
3.1. BM-MSCs disclose significant tropism for CM
from OS cells and strongly affect the metastatic
potential of cancer cells
In agreement with data from the literature showing
strong homing properties of BM-MSCs for several pri-
mary tumours, including OS (Barcellos-de-Souza et al.,
2016; Tsukamoto et al., 2012; Xu et al., 2009; Yu et al.,
2015), we demonstrated a significant chemotaxis of BM-
MSCs toward CM obtained from three different OS cell
lines (SaOS-2, MG-63 and HOS), with a 2- to 2.5-fold
increase in migration when compared with control (St
Med, Figs 1A and S1A). It has recently been reported
that stromal cell-derived factor 1 (SDF-1 or CXCL12) is
crucial to promote BM-MSCs homing to CM from
SaOS-2 cells (Xu et al., 2009). However, we excluded
the involvement of the CXCR4/SDF-1 axis in the OS-
dependent recruitment of BM-MSCs by performing
chemotaxis experiments with blocking antibodies
against CXCR4 (Figs 1B, S1B and S1C). Accordingly,
to identify the soluble factors involved in the BM-MSC
chemotaxis toward OS cells, CM derived from MG-63,
the cell line that showed the highest chemoattractant
abilities, was analysed by ELISA. We quantified estab-
lished inflammatory cytokines and growth factors that
have been shown to be involved in BM-MSC migration
in other cancer models (Fig. 1C; Barcellos-de-Souza
et al., 2013; Spaeth et al., 2008). Among the cytokines
produced, we focused our attention on those with the
highest levels of secretion: GRO-a (542 pgmL1  70),
MCP-1 (359.9 pgmL1  65) and TGF-b1
(1161.7 pgmL1  81), a pattern of cytokine expres-
sion common to other OS cell lines, as reported in sev-
eral studies (Chen et al., 2015; Giner et al., 2015; Liu
et al., 2017; Tu et al., 2014). To validate the role of
these chemokines in BM-MSC recruitment, we per-
formed transwell migration assays with the following
inhibitors: neutralizing antibodies against MCP-1 (a-
MCP-1), a TGF-b receptor blocker (TbR blk) and a
pharmacological inhibitor of the GRO-a receptor,
SB225002 (Boppana et al., 2014). As shown in Fig. 1D
(and in Fig. S1D), the treatment of MG-63-derived CM
with anti-MCP-1 antibodies, or the incubation of BM-
MSCs with SB225002 and TbR blk, significantly
reduces BM-MSC migration by about 50% compared
with untreated MG-63-derived CM. Moreover, the
combined treatment of all the compounds further rein-
forces this effect, confirming the key role of these cytoki-
nes in BM-MSC chemotaxis toward CM from tumour
cells. As control for MCP-1 blocking antibody, we used
normal mouse IgG, which did not significantly affect
BM-MSC chemotaxis toward CM from MG-63
(Fig. S1E). The effects of the treatments on cell viability
were checked by AnnV/PI staining (Fig. S1F).
Almost 50% of OS patients develop lung metastasis,
the foremost cause of death for this tumour (Kansara
et al., 2014; Meyers et al., 2011). Here, we investigated
whether the conditioning of OS cells by BM-MSCs
could affect the metastatic potential of cancer cells. OS
cells were incubated for 48 h with CM derived from
BM-MSCs, and their invasion and intravasation abili-
ties were analysed by transwell migration assays. We
found that the treatment of OS cells with CM from
BM-MSCs significantly increases tumour cell migra-
tion through either a Matrigel-coated membrane
Fig. 2. CM derived from OS cells stimulates the BM-MSCs trans-differentiation into CAF-like cells. (A) FACS analysis of NG-2 and CD31
expression in BM-MSCs treated for 48 h with CM OS cells. (B) BM-MSCs were stimulated for 48 h with CM from OS cells and a-SMA and
Col I-a1 expression was assessed by immunoblot analysis. Results are representative of four biological replicates. (C) Collagen contraction
assay of BM-MSCs treated for 24 h with St Med or HOS CM. Data are expressed as percentages of the relative area of collagen disc
following contraction in comparison with an empty well (mean  SD, n = 3 biological replicates performed in duplicate). * P < 0.05 vs. St
Med. (D) Migration assay of HOS cells stimulated for 48 h with CM derived from BM-MSCs previously activated or not activated by tumour
cells (CM BM-MSCs St/HOS). Cells were allowed to migrate toward complete medium (FBS 10%). Untreated cells (St Med) were used as
control. Results are the mean  SEM of three biological replicates. *** P < 0.001 vs. St Med. (E) Invasion and transmigration (F) assays of
HOS cells treated as in (D) (mean  SD, n = 3 independent experiments). ** P < 0.005 vs. St Med; *** P < 0.001 vs. St Med.
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(Figs 1E and S2A) or a monolayer of human umbilical
vein endothelial cells (HUVECs, Figs 1F and S2B),
thus suggesting the positive role of BM-MSCs in inva-
sive properties of OS cells.
3.2. BM-MSCs acquire a CAF-like phenotype
upon contact with tumour cells
Once engrafted into the tumour microenvironment,
BM-MSCs establish a cross-talk with cancer cells
which may promote the trans-differentiation of BM-
MSCs towards different tumour stromal cells, such as
pericytes, endothelial cells and cancer-associated
fibroblasts (CAFs; Barcellos-de-Souza et al., 2016;
Mishra et al., 2008). To determine whether soluble fac-
tors released by OS cells could stimulate a trans-differ-
entiation of BM-MSCs into vascular-like cells, BM-
MSCs were incubated for 48 h with CM derived from
OS cells and analysed by flow cytometry for the
expression of CD31 and neural/glial antigen 2 (NG2),
established markers of endothelial cells and pericytes,
respectively. As shown in Fig. 2A, following condi-
tioning with CM from OS cells, the levels of CD31
and NG2 in BM-MSCs are unaffected. To analyse a
possible trans-differentiation of BM-MSCs into CAF-
like cells, we assessed the expression of a-SMA and
collagen I-a1 in tumour-activated BM-MSCs by west-
ern blot analysis. As shown in Fig. 2B, the levels of
both proteins significantly increase after CM from OS
exposure. In keeping, the conditioning with CM from
HOS cells potentiates the contraction capacities of
BM-MSCs (Fig. 2C). These results confirm the trans-
differentiation of BM-MSCs towards a CAF-like phe-
notype upon contact with tumour CM.
Therefore, to investigate whether the acquisition of
this activated phenotype could enhance the pro-
tumourigenic activity of BM-MSCs, we prepared CM
either from BM-MSCs maintained in St Med (CM
BM-MSCs St) or stimulated with CM derived from
HOS cells (CM BM-MSCs HOS) for 48 h. HOS cells,
the cell line showing the highest invasion and migra-
tion potential (Fig. S3; Lauvrak et al., 2013; Ottaviano
et al., 2010), were treated for 48 h with CM and evalu-
ated for migration, invasion and transendothelial
migration abilities. We found that both BM-MSCs St
and BM-MSCs HOS potentiate the invasive behaviour
of OS cells, suggesting an increase of OS malignancy
induced by BM-MSCs despite their activation levels
(Figs 2D-F and S4A-C).
3.3. Cross-talk between BM-MSCs and OS guides
OS cells towards an amoeboid cell motility
To investigate in depth the molecular mechanism lead-
ing to increased invasion potential of OS cells induced
by BM-MSCs, we decided to investigate the activity or
expression of MMPs in OS cells conditioned with BM-
MSCs OS CM. As BM-MSCs St and BM-MSCs HOS
showed a similar effect on OS migration abilities, we
decided to use only CM derived from tumour-acti-
vated BM-MSCs in the following experiments to
mimic in vivo conditions. We proved, by gelatin
zymography, that all tumour cell lines secrete signifi-
cant amounts of pro-gelatinases MMP-2 and MMP-9
(Fig. 3A). HOS cells, the most aggressive OS cell line,
secrete the highest levels of these MMPs; however,
these do not increase following the treatment with CM
BM-MSCs HOS. MG-63 cells show a similar behaviour,
whereas SaOS-2 cells exhibit an increase in pro-MMP-
2 following 48 h of incubation with CM from BM-
MSCs SaOS. Next, we analysed the activation levels of
RhoA GTPase, a key regulator of amoeboid migra-
tion, and Rac1 GTPase, which is required for mes-
enchymal motility (Sanz-Moreno et al., 2008). The
contact with CM derived from tumour-activated BM-
MSCs induces a significant decrease of bound Rac1-
Fig. 3. Cross-talk between BM-MSCs and OS cells promotes the acquisition of an amoeboid-like motility in cancer cells. (A) Gelatin
zymography of CM obtained from SaOS-2, MG-63 and HOS cells stimulated or not stimulated for 48 h with CM derived from BM-MSCs
activated by each OS cell line (CM BM-MSCs OS). The white line indicates the junction of two different gels. Image is representative of
three independent experiments. (B) Representative images of pull-down assay of Rac1 and RhoA GTPases (left panel) and related
quantification (right panel). The assay was performed on OS cells grown for 48 h in CM from tumour-activated BM-MSCs (CM BM-MSCs
OS) or in starvation medium. Rac1-GTP and RhoA-GTP expression was normalized with respect to total Rac1 and RhoA in OS lysates.
### P < 0.001, Rac1-GTP CM BM-MSCs vs. Rac1-GTP St Med. * P < 0.05, RhoA-GTP CM BM-MSCs vs. RhoA-GTP St Med. Results are
presented as mean  SD of three biological replicates. (C) Confocal analysis of F-actin (FITC phalloidin) and P-MLC staining in MG-63 cells
treated or not treated with CM BM-MSCs MG63 for 48 h. Scale bar: 10 lm. The images are representative of three biological replicates
with similar results. (D) Live imaging of MG-63 cell migration in three-dimensional collagen lattice. CFSE-loaded MG-63 cells were
incorporated into the collagen matrix and monitored by confocal fluorescence-reflection video microscopy. Tumour cells are visualized in
green and the back-scatter signal of the collagen I is shown in white. On the left, arrows indicate the point at which MG-63, treated with ST
medium, shows an elongated morphology. In MG-63 cells treated for 48 h with CM from tumour-activated BM-MSCs (right), arrowheads
indicate the rounded shape of the cells squeezing across collagen I fibres. Scale bar: 20 lm.
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GTP with a parallel increase of bound RhoA-GTP in
OS cells. Notably, the CM treatment induces an
approximately two-fold increase in the RhoA/Rac1
ratio in all the OS cell lines tested (Fig. 3B, left and
right panels). These data suggest a shift in the migra-
tion strategy of OS cells from a mesenchymal-like to
an amoeboid-like motility. Moreover, confocal analysis
shows that following the treatment with CM derived
from tumour-activated BM-MSCs, MG-63 cells
acquire a rounded morphology and undergo a redistri-
bution of actin fibres (Fig. 3C). In keeping with this,
the active form of myosin light chain (P-MLC) local-
izes in cortical rings, similar to cells treated with the
RhoA activator, Calpeptin, whereas control cells (St
Med) display an elongated morphology and actin-
myosin cytoskeleton organized in parallel bundles
along the cytoplasm. The shift toward an amoeboid
motility style is also supported by live imaging of MG-
63 cells in a three-dimensional collagen lattice
(Fig. 3D). When exposed to three-dimensional matri-
ces of type I collagen, untreated MG-63 cells move
through a spindle-shaped mesenchymal and proteolytic
stage. The conditioning of MG-63 cells with CM from
tumour-activated BM-MSCs promotes a shift to a
rounded squeezing movement, independent of matrix
degradation. Finally, in line with a shift toward an
amoeboid-like motility, OS cells stimulated by tumour-
activated BM-MSCs display a lack of sensitivity to the
treatment with the MMPs inhibitor Ilomastat in both
invasion and transendothelial migration assays
(Fig. S5A,B). Interestingly, we observed a significant
increase in the levels of tissue inhibitor of MMP
(TIMP)-1 and -2 secretion in BM-MSCs stimulated for
48 h with CM from HOS and MG-63 cells (Fig. S6C).
These data suggest that the reciprocal interplay
between BM-MSCs and cancer cells promotes tumour
cell plasticity toward an amoeboid-like phenotype.
3.4. GRO-a, IL-6, IL-8 and MCP-1 produced by
BM-MSCs determine the migration plasticity of
OS cells
To identify the soluble factors produced by BM-MSCs
responsible for changes induced in the style of motility
of OS cells, we performed a cytokine assay of CM
derived from unconditioned and tumour-activated
BM-MSCs (Fig. 4A). The assay simultaneously detects
Fig. 4. BM-MSCs secrete a specific pattern of cytokines and
growth factors. (A) CM from BM-MSCs grown in St Med or HOS
CM was collected and analysed with Human Cytokine Antibody
Array according to manufacturer’s protocol. C5 (+) positive
controls; () negative controls; (1) GRO; (2) IL-6; (3) IL-8; (4) MCP-
1; (5) OPG; (6) TIMP-1; (7) TIMP-2. (B) Bar graph reporting the spot
density quantified on each membrane with IMAGEJ. Expression
values > 10 000 arbitrary units were set to identify a threshold for
cytokines to be considered.
Table 1. BM-MSCs isolated from two different healthy donors (BM-MSC 1 and 2) were grown to confluence, then serum-starved (St Med)
or stimulated with CM from HOS and MG-63 cells for 48 h. The media were replaced with St Med for another 24 h, then collected, clarified
by centrifugation and analysed by ELISA immunoassay for GRO-a, IL-6, IL-8 and MCP-1. The results are the mean  SD of three technical
replicates.
BM-MSC 1 BM-MSC 2
St Med CM HOS CM MG-63 St Med CM HOS CM MG-63
GRO-a 7 pg mL1  0.2 11 pg mL1  1 13 pg mL1  1 6 pg mL1  0.1 8 pg mL1  0.3 28 pg mL1  9
IL-6 11 pg mL1  3 24 pg mL1  5 700 pg mL1  190 79 pg mL1  13 223 pg mL1  13 6557 pg mL1  223
IL-8 6 pg mL1  0.3 50 pg mL1  6 177 pg mL1  20 10 pg mL1  2 42 pg mL1  12 382 pg mL1  73
MCP-1 89 pg mL1  21 598 pg mL1  151 647 pg mL1  120 783.9 pg mL1  151 1104.9 pg mL1  126 991.8 pg mL1  177
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80 different cytokines and growth factors. Among
these, we found detectable spots of GRO-a, IL-6, IL-
8, osteoprotegerin (OPG), a decoy receptor of
RANKL, MCP-1, TIMP-1 and TIMP-2. The relative
bar plot is depicted in Fig. 4B. Expression values
> 10 000 arbitrary units were set to identify a thresh-
old for cytokines to be considered. To verify whether
different OS cell lines share this pattern of cytokines
and GFs, we stimulated BM-MSCs isolated from two
different donors with CM from both HOS and MG
cells. Levels of GRO-a, IL-6, IL-8 and MCP-1 were
measured by ELISA immunoassay (Table 1). As
shown, we demonstrated that even if some differences
in cytokines concentration are present at the basal
level, most probably due to intra-individual variability,
the amount of these cytokines is similar between the
two isolations. Furthermore, the increase of cytokine
expression following conditioning with CM from both
OS cell lines follows exactly the same trend, suggesting
the crucial role of these cytokines in promoting aggres-
siveness of OS cell lines. To validate the role of these
factors in modulating the migration abilities of cancer
cells, HOS cells stimulated with CM BM-MSCs HOS
were treated or not treated with neutralizing antibodies
against IL-6, IL-8, MCP-1 and SB225002, and then
analysed for invasion and transmigration. As depicted
in Figs 5A and S7A, the invasion of cancer cells is
strongly dependent on this pattern of cytokines. In
particular, IL-6 and GRO-a blockade drastically
impairs HOS cell invasion. On the other hand, HOS
transmigration is significantly affected by IL-8 and
MCP-1 inhibition, but blocking GRO-a signalling does
not affect the migration of cancer cells across the
endothelial monolayer (Figs 5B and S6B). To evaluate
the specificity of treatment, normal mouse IgG was
used as control (Fig. S6C). As the combined treatment
with all the inhibitors leads to a strong decrease of cell
viability (almost 60%) following 24 h of incubation
with inhibitors, we excluded this condition from the
experimental settings (Fig. S6D).
3.5. Reciprocal interplay between BM-MSCs and
OS cells stimulates in vitro angiogenesis
The formation of new vessels is a key prerequisite to
ensure the metastatic dissemination of cancer cells.
Moreover, as the cross-talk between BM-MSCs and
OS cells greatly affects their transendothelial migration
capacities, we decided to investigate whether this inter-
play could also influence the activation of endothelial
cells. First, quantitative RT-PCR analysis revealed an
increase in the mRNA levels of VEGF and IL-8, two
of the major activators of angiogenesis, in HOS or
MG-63 cells maintained for 48 h in St Med or CM
from BM-MSCs conditioned by OS cells (Fig. 6A,B).
To confirm the expression of VEGF and IL-8 at pro-
tein level, measurements were taken using a cytokine
array a panel of pro-angiogenic factors in CM derived
from HOS cells maintained in St Med or stimulated
with CM from tumour-activated BM-MSCs for 48 h.
As shown in Fig. 6C, HOS cells activated with CM
Fig. 5. The pro-tumourigenic activities of BM-MSCs depend on
GRO-a, IL-6, IL-8 and MCP-1 secretion. (A) Invasion assay of HOS
cells treated with CM BM-MSCs HOS supplemented or not
supplemented with neutralizing antibodies against IL-6 (5 lgmL1),
IL-8 (10 lgmL1) and MCP-1 (10 lgmL1) and GRO-a receptor
inhibitor (SB 225002, 200 nM). Results are presented as mean 
SEM of three biological replicates. ** P < 0.005 CM BM-MSCs HOS
vs. CM BM-MSCs HOS + a-IL-8 and CM BM-MSCs HOS vs. CM BM-
MSCs HOS + a-MCP-1; *** P < 0.001, CM BM-MSCs HOS vs. CM
BM-MSCs HOS + a-IL-6; §§§ P < 0.001, CM BM-MSCs HOS vs. CM
BM-MSCs HOS + SB 225002. (B) Transendothelial migration assay
of HOS cells treated as in (A) (mean  SEM, n = 3 biological
replicates). * P < 0.05, CM BM-MSCs HOS vs. CM BM-MSCs
HOS + a-IL-6; ** P < 0.005, CM BM-MSCs HOS vs. CM BM-MSCs
HOS + a-IL-8; *** P < 0.001, CM BM-MSCs HOS vs. CM
BM-MSCs HOS + a-MCP-1.
669Molecular Oncology 12 (2018) 659–676 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
L. Pietrovito et al. Cross-talk between BM-MSCs and osteosarcoma cells
670 Molecular Oncology 12 (2018) 659–676 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Cross-talk between BM-MSCs and osteosarcoma cells L. Pietrovito et al.
from BM-MSCs secrete higher amounts of VEGF, IL-
8, angiopoietin (ANG) and platelet-derived growth
factor BB (PDGF-BB). We then evaluated the ability
of HOS cells to recruit endothelial cells in both
chemoattraction and invasion assays. To this end,
HUVECs were allowed to migrate toward or to invade
CM HOS St or CM HOS BM-MSCs. As shown in
Figs 5(C,D) and S7(A,B), the interplay between BM-
MSCs and HOS cells strongly potentiates both
chemoattraction and invasiveness of endothelial cells.
Similarly, we demonstrated that this cross-talk is cru-
cial to stimulate the capillary network formation
in vitro, already appreciable following 6 h of treatment
(Fig. 6F). These results strongly support the idea that
in OS stroma, BM-MSCs and cancer cells co-operate
to promote tumour vascularization, a central phe-
nomenon for cancer growth and metastasis.
4. Discussion
The tumour microenvironment is a complex and
dynamic milieu consisting of cells, signalling molecules
and ECM that supports tumour growth and progres-
sion. Here, we investigated the effects induced by the
cross-talk between BM-MSCs and OS cells on tumour
malignancy. We found that BM-MSCs are efficiently
recruited by three different OS cell lines (SaOS-2, MG-
63 and HOS) and, for the first time, we identified
MCP-1, GRO-a and TGF-b-1 as key molecules in pro-
moting this migration. Moreover, we showed that fol-
lowing contact with CM from OS cells, BM-MSCs are
stimulated to trans-differentiate into CAF-like cells.
The interaction between BM-MSCs and OS cells is
bidirectional: the mesenchymal stroma activated by
tumour cells secrete higher levels of IL-6, IL-8, GRO-
a and MCP-1 in the tumour microenvironment. OS
cells replay the changes of the microenvironment
through a MAT, further enhancing their invasiveness
and transendothelial migration abilities. Moreover, the
interplay between BM-MSCs and OS cells significantly
affects the activation of endothelial cells in terms of
invasion, migration and capacity to form a capillary
network. Here, we characterized the response of three
different OS cell lines. These cells significantly diverge
from each other in genetic alteration, morphology,
aggressiveness and proliferation kinetics (Lauvrak
et al., 2013; Mohseny et al., 2011). In particular,
SaOS-2 cells show a phenotype very close to that of
normal mesenchymal precursors, whereas HOS cells,
which are extremely aggressive, display a smaller and
hexagonal morphology, similar to epithelial cells. The
MG-63 cells have an intermediate phenotype between
the other two OS cell lines. Following contact with
CM from BM-MSCs, SaOS-2 cells seem to behave in
a different manner compared with MG-63 and HOS
cells with regard to cell migration and MMP expres-
sion, as well as secretion of pro-angiogenic factors.
This is probably due their striking mesenchymal phe-
notype and a basal aggressiveness that is lower than
that of the other two lines. However, SaOS-2 cells
showed the most remarkable reduction of the active
form of Rac-1, underlining that the mesenchymal stro-
mal compartment can strongly affect the tumour cell
phenotype and thus the OS evolution.
It is now well established that several chemokines
and growth factors are involved in the mobilization
of BM-MSCs from the bone to the stroma of
different tumours, such as glioma, breast, prostate,
ovarian, pancreatic and lung carcinoma (Barcellos-de-
Souza et al., 2013; Spaeth et al., 2008; Xu et al.,
2009). Notably, in this study, we show that OS-
dependent recruitment of BM-MSCs is supported by
a specific pattern of cytokines including MCP-1,
GRO-a and TGF-b1. Moreover, we excluded the
involvement of CXCR4/SDF-1 axis in this migration.
In agreement with our results, several reports indicate
that BM-MSCs secrete high levels of SDF-1 but
express low levels of CXCR4, whereas OS cells
release small amounts of SDF-1 but express elevated
levels of CXCR4, crucial to promote the metastatic
spread of the tumour to the lung (Perissinotto et al.,
2005; Ponte et al., 2007; Yu et al., 2015).
Fig. 6. Cross-talk between BM-MSCs and OS cells stimulates the recruitment and activation of endothelial cells. (A,B) Quantitative RT-PCR of
VEGF and IL-8 mRNA expression in OS cells maintained in St Med or CM BM-MSCs OS for 48 h. Results are presented as mean  SD of
three biological replicates. * P < 0.05 vs. St Med; *** P < 0.001 vs. St Med. (C) Semi-quantitative detection of pro-angiogenic factors in CM
derived from HOS cells stimulated with CM from tumour-activated BM-MSCs in comparison with CM derived from BM-MSCs maintained in
St Med for 48 h. CM were collected and analysed with Human Cytokine Antibody Array according to manufacturer’s protocol reported in
Material and Methods. (D) Migration assay of HUVEC cells towards CM derived from HOS St or HOS BM-MSCs. Results are mean  SEM from
three independent experiments. ** P < 0.05 vs. St Med; *** P < 0.001 vs. St Med. (E) Invasion assay of HUVEC cells treated as in (D).
Results are expressed as mean  SEM of three biological replicates.** P < 0.05 CM HOS BM-MSCs vs. CM HOS St; *** P < 0.001 CM
HOS BM-MSCs vs. CM HOS St. (F) Capillary morphogenesis assay of HUVECs incubated in CM from HOS St or HOS BM-MSC. Cord formation
was examined after 6 h at 37 °C with optical microscope. The total number of junctions is presented as mean  SEM of three randomly
chosen fields for each experimental condition of three biological replicates performed in technical duplicate. ** P < 0.05 vs. St Med.
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Several studies hae shown that, once engrafted into
the tumour microenvironment, BM-MSCs are able
directly to aid tumour growth and progression. Here,
we show that BM-MSCs promote both invasion and
transendothelial migration of OS cells, suggesting an
increase in the metastatic potential of cancer cells. This
observation is in agreement with data showing that
cytokines secreted by BM-MSCs not previously in con-
tact with cancer cells, can directly support prolifera-
tion and migration of tumour cells (Karnoub et al.,
2007; Martin et al., 2010; Tsai et al., 2011; Xu et al.,
2009).
It is well known that, following cytokine and growth
factor stimulation, BM-MSCs trans-differentiate into
different stromal components, leading to promotion of
tumour malignancy. Herein, we have proved that fol-
lowing contact with CM from OS cells, BM-MSCs
trans-differentiate into a-SMA-expressing fibroblasts,
normally identified as CAFs. Surprisingly, we noticed
that activated CAF-like BM-MSCs induce a similar
increase in the migratory/invasive abilities of OS cells
with respect to non-activated BM-MSCs. Most proba-
bly because we tested only standard conditions (with-
out hypoxia or acidosis), and also because OS is a
mesenchymal tumour with a basal, very high aggres-
siveness, as demonstrated by the early development of
pulmonary metastasis, this resulted in high patient
mortality. Thus, it is very hard to further enhance this
malignant behaviour.
We have now demonstrated that recruited BM-
MSCs promote a shift toward an amoeboid phenotype
in OS cells. As a consequence, OS cells potentiate
their invasion and transendothelial migration, increas-
ing their metastatic potential. In keeping with our
results, Cortini et al. (2016) have recently demon-
strated that IL-6 secreted by the mesenchymal stroma
is essential to promote OS stemness and migratory
potential. In line with this, a previous work by our
group indicated that CAFs co-operate with endothelial
progenitor cells to engage a clear MAT in prostate
cancer cells (Giannoni et al., 2013). This shift in motil-
ity style is crucial to promote cancer cell adhesion to
endothelium and transendothelial migration. MAT has
been described as an essential adaptive programme
conferring significant advantages during the metastatic
dissemination. To date, very little is known about the
molecular mechanisms that govern this transition. It is
widely accepted that growth factors and cytokines
released by either tumour cells themselves or stromal
cells not only control and direct the migration routes
of tumour cells, but also modulate their plasticity,
invasiveness and metastatic dissemination (Odenthal
et al., 2016). It has been recently proved that
metastatic sarcoma cells show an up-regulation of
RhoA/ROCK signalling compared with parental non-
metastatic cells (Belgiovine et al., 2010; R€osel et al.,
2008; Zucchini et al., 2014). In the present study, we
showed that BM-MSCs promote MAT in OS cells
through the secretion of a specific pattern of cytokines:
GRO-a, IL-6, IL-8 and MCP-1. Using specific inhibi-
tors, we demonstrated that each of these cytokines, par-
ticularly IL-6 and GRO-a, modulates the invasive
behaviour of tumour cells, whereas the mechanism of
transendothelial migration is completely independent of
GRO-a/CXCR2 signalling. In keeping with our results,
it has been reported that in squamous carcinoma cells,
melanoma and stromal fibroblasts, IL-6 pathway acti-
vates ROCK and generates a high level of actomyosin
contractility (Sanz-Moreno et al., 2011). Moreover, it
has been shown that the activation of IL-8 signalling
pathways leads to RhoA activation and actin stress fibre
formation in cancer and endothelial cells (Schraufstatter
et al., 2001; Waugh and Wilson, 2008). Finally, several
studies have indicated that MCP-1 secreted by tumoural
and stromal cells induces transendothelial migration of
T cells, monocytes, smooth muscle cells and adult neural
stem cells (Cai et al., 1996; Ma et al., 2007; Widera
et al., 2004). Interestingly, we showed that the pattern
of cytokines secreted by both BM-MSCs and OS cells is
very similar, confirming the common mesenchymal ori-
gin of these two cell types (Kansara et al., 2014; Meyers
et al., 2011). Most likely, the recruitment of BM-MSCs
to the tumour site promotes a local increase of the
cytokines which are already produced by tumour cells
themselves. Thus, both cell populations concurrently
contribute to the generation of a milieu enriched in
cytokines, which stimulates in an additive manner the
migratory and invasive properties of OS cells.
Finally, we stress that the cross-talk between BM-
MSCs and OS cells on the one hand stimulates the
secretion of pro-angiogenic factors in tumour cells,
and on the other stimulates both the recruitment and
the invasion of endothelial cells, as well as their capac-
ity to form in vitro tubular-like structures. The forma-
tion of new vessels combined with increased
transendothelial migration of OS cells are additive
events concurrently promoting the metastatic dissemi-
nation of cancer cells.
Our data indicate that the recruitment of BM-MSCs
into the OS stroma is a crucial event to promote
tumour progression. Therefore, both recruitment of
BM-MSCs to the OS site and cytokine-induced MAT
of tumour cells represent innovative targets to test
in vivo OS models to design innovative therapeutic
approaches aiming to hinder the metastatic dissemina-
tion of OS cells.
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5. Conclusions
Our data indicate that the recruitment of BM-MSCs
into the OS stroma is a crucial event to promote
tumour progression. Indeed, once in contact with
tumour cells, BM-MSCs trans-differentiate into CAFs,
strongly increasing GRO-a, MCP-1, IL-6 and IL-8
levels in the tumour microenvironment. These cytoki-
nes are crucial to induce a MAT in OS cells, with a
consequent rise of their migration abilities, invasive-
ness and transendothelial migration. Moreover, in
response to these microenvironmental changes, tumour
cells significantly increase their capacity to induce
tumour de novo angiogenesis, a key step to ensure the
metastatic dissemination of cancer cells. Therefore, our
results include both recruitment of BM-MSCs to the
OS site and their transendothelial migration due to
MAT as innovative targets to test in vivo OS models
in order to design new therapeutic approaches aiming
to impair the metastatic dissemination of OS cells.
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Fig. S1. (A,B) Representative images of BM-MSC
chemotaxis toward CM from OS cells in the presence
or absence of CXCR4 inhibitor 20 lgmL1. (C)
3.5 9 105 BM-MSCs were serum-starved for 24 h in
the presence of a-CXCR4 or normal mouse IgG
(20 lgmL1), then allowed to migrate overnight
toward CM from OS cells. (D) Representative images
of BM-MSC migration in the presence of specific inhi-
bitors of MCP-1, GRO-a and TGF-b (see Material
and Methods for more details). (E) 3.5 9 105 BM-
MSCs were serum-starved for 24 h and allowed to
migrate toward CM from MG-63 cells supplemented
or not supplemented with neutralizing antibodies
against MCP-1 or with normal mouse IgG.; ***
P < 0.001 vs. St Med. (F) 3.5 9 105 BM-MSCs were
starved overnight in the presence or absence of 200 nM
SB225002, 100 lgmL1 TbR blk and both inhibitors
(Combo). Cells were then detached, centrifuged, resus-
pended in MuseTM Count and Viability buffer (1 9 105
cellsmL1) and cell viability assessed with Muse Cell
Analyzer according to manufacturer’s instructions.
Fig. S2. Representative images of OS cell invasion (A)
and transendothelial migration (B) (see Results section
for more details).
Fig. S3. 1.5 9 105 OS cells (Saos-2, MG-63 and HOS)
were starved overnight and allowed to migrate for 16 h
toward complete medium (FBS 10%). Mean  SEM of
two biological replicates performed in triplicate.
Fig. S4. Representative images of HOS cell migration
(A), invasion (B) and transendothelial migration (C)
(see Results section for more details).
Fig. S5. OS cells were cultured for 48 h in St Med or
CM derived from tumour-activated BM-MSCs (CM
BM-MSCs OS) supplemented or not supplemented with
MMP inhibitor Ilomastat, 50 lM. The invasion (A) or
transendothelial migration (B) was evaluated by count-
ing migrating cells in four randomly chosen fields
(mean  SEM, n = 3 biological replicates). * P < 0.05
St Med vs. St Med + Ilo; ** P < 0.01 St Med vs. CM
BM-MSCs OS; *** P < 0.001 St Med vs. CM BM-
MSCs OS; # P < 0.05 St Med vs. CM BM-MSCs OS +
Ilo; ## P < 0.01 St Med vs. CM BM-MSCs OS + Ilo;
### P < 0.001 St Med vs. CM BM-MSCs OS + Ilo.
(C) 3.5 9 105 BM-MSCs were starved (St Med) or
conditioned with CM from HOS and MG-63 cells for
48 h. BM-MSCs were then starved for a further 24 h
and media were collected, centrifuged and analysed by
ELISA for quantification of TIMP-1 and -2. Results
are expressed as mean  SD of three biological repli-
cates. * P < 0.001 vs. St Med.
Fig. S6. Representative images of HOS invasion (A)
and transendothelial migration (B) in the presence of
specific inhibitors of IL-6, IL-8, MCP-1 and GRO-a
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activity (see Results section for more details). (C) To
evaluate whether the treatment with neutralizing anti-
bodies could basically affect the migration abilities of
cancer cells, 5 9 104 HOS cells were treated for 48 h
with CM from tumour-activated BM-MSCs in the
presence or absence of normal mouse IgG 5 and
10 lgmL1. The mock antibodies did not significantly
change HOS invasion. (D) 3.5 9 105 HOS cells were
maintained for 24 h in starvation medium (St Med) or
in CM from tumour-activated BM-MSCs (CM BM-
MSCs HOS) in the presence or absence of neutralizing
antibodies against IL-6 (5 lgmL1), IL-8
(10 lgmL1), MCP-1 (10 lgmL1), SB225002
(200 nM) and all inhibitors (Combo). Cells were then
detached, centrifuged, resuspended in MuseTM Count
and Viability buffer (1 9 105 cellsmL1) and assessed
with Muse Cell Analyzer according to the manufac-
turer’s instructions.
Fig. S7. Representative images of HUVEC migration
(A) and invasion (see Results section for more details).
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